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Anthracyclines and taxanes are amongst the most active single
agents in advanced breast cancer. Studies of single agent paclitaxel
demonstrate that leucopenia is frequent and dose-limiting in all
schedules (3-, 6-, 24-h infusion) evaluated. Randomized trials
evaluating the 3- and/or 24-h schedules, each with two paclitaxel
doses of 135 and 175 mg m–2, have revealed that neutropenia is
dose- and schedule-dependent, without apparent difference in effi-
cacy (Eisenhauer et al, 1994; Nabholtz et al, 1996; Gianni et al,
1995a). The optimal therapeutic schedule of paclitaxel is still
unknown and, on practical grounds, the short infusion over 3 h is
safe, convenient and effective (Gianni, 1995b).
Paclitaxel at longer infusion rate (³ 24 h) has been given in
combination with doxorubicin. The maximal tolerable dose
(MTD) and toxicity profile (primarily mucositis and neutropenia)
of this combination appear to depend on the sequence and infusion
duration of the two drugs (Fisherman et al, 1993; Sledge Jr et al,
1994). In a study of escalating doses paclitaxel (3-h infusion) in
combination with fixed dose of doxorubicin (60 mg m–2 i.v. bolus)
in a 3-weekly schedule, mucositis, long-lasting grade 4 neutro-
penia and febrile neutropenia defined the MTD of paclitaxel at 
200 mg m–2, and was not sequence dependent. This regimen was
very effective in chemotherapy-naive breast cancer patients, but at
the cost of considerable increased cardiotoxicity (Gianni et al,
1995c; Gehl et al, 1996). 4¢-Epi-doxorubicin (epirubicin) is a
synthetic doxorubicin analogue, with similar anti-tumour activity
as doxorubicin at equimolar doses, but decreased overall toxicity,
in particular cardiotoxicity (Brambilla et al, 1986; Jain et al, 1985).
It may, therefore, be an attractive substitute for doxorubicin in
combination with taxanes.
Granulocyte colony stimulating factor (G-CSF) can be used to
ameliorate neutropenia and to obtain increased dose-intensity by
allowing a higher dose of chemotherapy per cycle (dose-escala-
tion) or by allowing a shortening of the interval between cycles
(dose-dense). Both approaches may lead to a higher dose-intensity,
but their biological effect and clinical relevance may be quite
different (Henderson et al, 1988). Dose-dense chemotherapy may
be important to overcome the cellular cytokinetic resistance of
tumors (Gilewski and Norton, 1996). Dose-escalation is based on
a steep dose–response relationship, whereby the doses of
chemotherapy are increased up to the limits of haematological and
non-haematological toxicity. These two approaches were investi-
gated by our group in the treatment of metastatic breast cancer
with epirubicin and cyclophosphamide. With the addition of G-
CSF, interval reduction permitted a higher dose-intensity, with less
toxicity, than dose escalation (Lalisang et al, 1997). Based on these
results we started a study with the aim of increasing the dose-
intensity of a conventional dose of epirubicin (75 mg m–2 i.v.
bolus) and paclitaxel (135 mg m–2 3-h infusion) combination by
shortening of the cycle time. We intended to define the minimal
tolerable interval of this chemotherapy regimen in combination
with G-CSF support. During the study the protocol was amended,
and allowed testing a higher paclitaxel dose of 175 mg m–2 in the
shortest feasible interval. The second aim was to assess the safety
profile of this approach.
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Summary Anthracyclines and taxanes are very effective drugs in the treatment of advanced breast cancer. With G-CSF support, the dose-
intensity of this combination can be increased by reducing the interval between chemotherapy cycles, the so-called ‘shortening of cycle time’.
We treated 36 patients with advanced breast cancer in a multicentre phase I/II study. The treatment regimen consisted of epirubicin 75 mg m–2
followed by paclitaxel 135 mg m–2 (3 h) in combination with G-CSF. At least six patients were treated in each cohort and were evaluated over
the first three cycles. Starting at an interval of 14 days, in subsequent cohorts of patients the interval could be shortened to 10 days. An 8-day
interval was not feasible due mainly to incomplete neutrophil recovery at the day of the next scheduled cycle. In the 10-day interval cohort it
was feasible to increase the paclitaxel dose to 175 mg m–2. The haematological and non-haematological toxicity was relatively mild. No
cumulative myelosuppression was observed over at least three consecutive cycles. In combination with G-CSF, epirubicin 75 mg m–2 and
paclitaxel 175 mg m–2 could be safely administered every 10 days over at least three cycles, enabling a dose intensity of 52 and 122 mg m–2
per week, respectively. © 2000 Cancer Research Campaign
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Patient selection
The study protocol was approved by the institutional review
boards of the participating hospitals, and patients gave informed
consent. Women with advanced breast cancer had to fulfil the
following inclusion criteria:
• Histological proof of breast cancer
• Age 18–70 years
• Performance status 0–2 (Eastern Cooperative Oncology Group
scale)
• Neutrophil count ³ 2 ´ 109 l–1 and platelet count ³ 100 ´ 109 l–1
• Adequate function tests for liver (bilirubin level < 25 mmol l–1
and transaminase level (< 3 ´ upper limit of normal) and
kidneys (serum creatinine level < 150 mmol l–1)
• No prior chemotherapy for metastatic disease
• Prior adjuvant chemotherapy allowed, if interval last
chemotherapy cycle ³ 1 year and at entry lifetime cumulative
dose of doxorubicin ≤ 300 mg m–2 and epirubicin ≤ 450 mg m–2
• Prior radiotherapy involving ≤ 25% of red bone marrow
• Left ventricle ejection fraction (LVEF) by multigated (MUGA)
isotope cardiograph ³ 50% and without symptomatic cardio-
vascular disease
• No central nervous system involvement.
Treatment plan
In this schedule-finding study, the epirubicin (Pharmacia &
Upjohn, Milan, Italy), paclitaxel (Taxol, Bristol-Myers Squibb
Pharmaceuticals, Princeton, NJ, USA) as well as R-metHuG-CSF
(Filgrastim, Amgen Inc., Thousands Oaks, CA, USA) doses were
kept constant, and four intercyclic intervals were foreseen. The
starting interval of 14 days was planned to be decreased to 12, 10
and 8 days, respectively. To prevent hypersensitivity reactions due
to paclitaxel, a routine premedication regimen was adopted: oral or
intravenous dexamethasone 20 mg (6 and 12 h pre-treatment);
clemastine 2 mg and ranitidine 50 mg both intravenously 30–
60 min before paclitaxel administration. Epirubicin was given as a
short i.v. infusion on day 1 at a fixed dose of 75 mg m–2. Paclitaxel
at a dose of 135 mg m–2 was administered by a 3-h infusion,
starting 5 min after epirubicin administration. G-CSF (300 mg for
patients ≤ 70 kg and 480 mg for patients > 70 kg) was administered
once daily subcutaneously on all days except the days of
chemotherapy.
A cohort of at least six patients was studied at each interval. The
neutrophil (³ 2 ´ 109 l–1) and platelet (³ 100 ´ 109 l–1) counts had to
have recovered on the day of scheduled chemotherapy. For this
study specific dose-intensity limiting criteria (DILC, see Table 1)
had been defined. Proceeding to the next, shorter, interval level
was only done after completion of the previous cohort and if less
than 50% of those patients had experienced a DILC during the first
three courses. In case of incomplete haematological recovery treat-
ment was delayed. Concomitant hormonal therapy or prophylactic
antibiotic therapy was not allowed. Patients were transfused when
necessary to maintain a platelet count of ³ 15 ´ 109 l–1 and haemo-
globin level ³ 6 mmol l–1.
The patients had to complete a minimum of three cycles, except
if one of the following events occurred: disease progression,
DILC, any other unacceptable toxicity precluding further therapy,
or patients’ refusal to continue treatment. After completion of the
first three cycles further therapy was left to the discretion of the
investigator.
As the 8-day interval appeared to be not feasible (see Results) a
new cohort was tested with a 10-day interval but using a higher
paclitaxel dose of 175 mg m–2.
The minimal tolerable interval (MTI) for this study was defined
as the shortest interval that resulted in less than 50% instances of
DILCs among treated patients in each cohort. To express the dose-
intensity of the treatment the equation, delivered dose-intensity
(DDI), the actually given dose per m2 per week during the first
three protocol cycles of treatment, was used.
Pre-treatment and follow-up evaluation
All patients were initially evaluated with a history, physical exami-
nation, complete blood-cell count (CBC), liver and kidney function
tests, ECG, LVEF MUGA scan, chest X-ray and bone scan. If indi-
cated additional radiological examinations of suspected areas, with
tumour measurements (if possible) were performed. CBC was
repeated twice weekly and a biochemical profile was assessed
before each cycle. Follow-up LVEF MUGA scan was requested
after three cycles, in case of clinical signs of congestive heart failure,
if patients went off study or at a cumulative dose of 500 mg m–1, at
800 mg m–2 of epirubicin and subsequently before each additional
treatment course thereafter. In our study cardiac toxicity was defined
as development of clinical cardiac failure and/or an absolute
decrease in resting LVEF either ³ 20% (EF absolute units) from
baseline to a value above 50% or ³ 10% to a value below 50%.
Tumour evaluation was repeated after each three cycles, at the
end of treatment or as clinically indicated and evaluated according
to UICC-criteria (Miller et al, 1981). Toxicity was assessed after
each course according to WHO grading criteria (Miller et al, 1981)
except for neutropenia, thrombocytopenia, febrile neutropenia and
cardiotoxicity for which adjusted criteria were applied (Table 1).
RESULTS
Patient characteristics
Forty-one eligible patients were entered, and five patients were
found to be not evaluable; four patients in the 8-day interval
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Table 1 Dose-intensity limiting criteria
1 Any WHO grade 3 or 4 non-haematological toxicity
2 Neutropenia grade 4: neutrophil count < 0.5 ´ 109 l–1 for a period of 
more than 7 days
3 Febrile neutropenia: neutrophil count < 0.5 ´ 109 l–1 and fever
4 Thrombocytopenia grade 4: platelet count < 25 ´ 109 l–1 for more than 
4 days
5 Delay of chemotherapy due to incomplete recovery on the day of 
scheduled therapy:
Haematological: neutrophil count < 2 ´ 109 l–1 and/or platelet count
< 100 ´ 109 l–1
Persistence of non-haematological side-effects of WHO grade 2 or 
more (excluding alopecia and anticipatory nausea and vomiting)
6 Cardiotoxicity, defined by development of clinical cardiac failure or an 
absolute decrease in MUGA LVEF ³ 20% (EF absolute units) from 
baseline to a value above 50% or ³ 10% (EF absolute units) to a value
below 50%(protocol violations after cycle 1 [two patients] and central venous
line complications [two patients]) and in the 10-day interval with
paclitaxel 175 mg m–2 one patient (too low G-CSF dose).
Therefore, 36 patients were fully assessable for the present report.
The characteristics of these 36 patients are shown in Table 2.
These 36 patients received 131 cycles according to the protocol
until DILC or protocol completion.
Initial dose-intensity limiting criteria in the first three
consecutive cycles
In this study analysing shortening of intervals with fixed doses of
epirubicin and paclitaxel 75/135 mg m–2, six patients were entered
at the starting interval of 14 days. One patient had an incomplete
platelet recovery at scheduled cycle 2 and a transient pathological
decrease of the LVEF after cycle 2 (Table 3). At the 12-day
interval one out of eight patients met a DILC: nausea/vomiting
WHO grade 3 after the third cycle. In the 10-day interval one out
of 10 patients had a DILC: an incomplete neutrophil recovery after
cycle 3. At the 8-day interval four out of six patients met a DILC
during the first three cycles, making this interval not feasible based
on the predefined criteria. The initial DILCs were: incomplete
neutrophil recovery at scheduled cycle 2 in three patients and
combination of febrile neutropenia, pulmonary embolism and
mucositis WHO grade 3 after cycle 2 in the fourth patient. Ten
days was the shortest feasible interval for epirubicin/paclitaxel
75/135 mg m–2 with G-CSF and the median DDI for the first three
cycles was 52 (range 49–56) mg m–2 per week and 94 (range
88–100) mg  m–2 per week, respectively.
To investigate whether the dose of paclitaxel could be increased
in the 10-day interval epirubicin/paclitaxel 75/175 mg m–2 was
tested. Two out of six patients encountered a DILC, transient
asymptomatic pathologic decrease in cardiac LVEF after the third
course, and infection (pneumonia) grade 2 at scheduled cycle 4,
respectively. The median DDI in the first three cycles was epiru-
bicin 52 (52–53) mg m–2 per week and paclitaxel 122 (117–126)
mg m–2 per week.
Cumulative toxicity
In the 14-day interval all five patients without a DILC in the first
three cycles continued at their scheduled interval for at least six
cycles. In the 12-day interval seven out of eight patients continued
the same chemotherapy combination after three protocol cycles,
although only two patients at scheduled interval for a total of four
cycles, all without additional toxicities.
In the 10-day interval three out of 10 patients continued sched-
uled treatment for a total of four (two patients) and nine (one
patient) cycles, respectively. The single patient with an incomplete
neutrophil recovery after cycle three developed a reversible
neuropathy grade 3 after cycle 6. In the 8-day interval the two
patients without a DILC in the initial three cycles continued the
scheduled interval for a total of five and six cycles, respectively.
The patient with a febrile neutropenia and stomatitis grade 3 after
the second cycle also developed pulmonary embolism. In the 10-
day interval at 75/175 mg m–2 only one patient continued sched-
uled treatment for six cycles. The kinetics of neutrophil and
platelet counts for the patients in the various intervals are shown in
Figure 1. The non-haematological toxicitys were generally mild
and are displayed in Table 4. Only one patient encountered a
hypersensitivity reaction WHO grade 2.
Transfusion of blood products
In this dose-dense schedule, during the first three cycles red blood-
cell (RBC) transfusions were needed in five patients. Most transfu-
sions occurred in the patients receiving more than three cycles (14
of 27 patients). Platelet transfusions were not given.
Cardiotoxicity
A total of 98 MUGA scans were performed; basal and follow-up
scans were available in 35 of 36 patients, making them evaluable
for cardiotoxicity by ejection fraction. A pathological decline in
LVEF, as defined earlier, was observed in two (6%) patients in the
first three cycles, both not pre-treated with anthracyclines. The
first patient (previously irradiated parasternally) was treated in the
14-day interval, developed a delayed platelet recovery after the
first cycle, received cycle 2 after platelet recovery, which was
complicated by severe dyspnoea and anaemia (4.5 mmol l–1), with
a transient decrease in LVEF (63®49%). On physical examina-
tion, chest X-ray and ECG no signs of congestive heart failure
were observed. After RBC transfusion the patient recovered and a
control LVEF showed normalization (62%). This patient
continued sheduled treatment for an additional three cycles,
without further signs of cardiac failure. A short interval (1 day)
between irradiation of the lumbar spine and start of study treat-
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Table 2 Patient characteristics
Eligible/evaluable for toxicity 36
Median age (range) 51 (24–68)
Performance ECOG 0/1/2 14/18/4
Adjuvant chemotherapy 14
Including anthracyclines 5
Previous chest/breast irradiation 28
Sites of disease in patients (% of all patients)
Bone 64%
Soft tissue 81%
Lung 36%
Liver 47%
Lung and/or liver 61%
No. of organs involved
Median (range) 2 (1–5)
Table 3 Epirubicin/Paclitaxel + G-CSF: Initial dose-intensity limiting criteria
in the first three cycles
Dose EP mg m–2 75/135 75/135 75/135 75/135 75/175
Interval days 14 12 10 8 10
Evaluable patients 6 8 10 6 6
Patient(s) with DILC 1 1 1 4 2
DILC
ANC-recovery – – 1 3 –
Platelet-recovery 1 – – –
Febrile neutropenia – – – 1a –
Mucositis ³ grade 3 – – – 1# –
Nausea/vomiting ³ 3–1 – – –
Infection – – – – 1
Cardiotoxicity 1 – – – 1
a Same patient with concurrent febrile neutropenia and mucositis grade 3
after cycle 2Dose-dense chemotherapy in metastatic breast cancer 1917
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ment may explain these transient DILCs. In the second patient
(previously irradiated to the right chest wall) after three cycles in
the 10-day interval at a dose of 75/175 mg m–2 an asymptomatic
decrease in LVEF (60®49%) was observed. The patient continued
with three cycles of epirubicin/cyclophosphamide with complete
normalization of the LVEF. From 20 patients cardiac evaluation
was available with a cumulative epirubicin dose of ³ 450 mg m–2;
median baseline LVEF 60% (range 50–72%) to 58% (range
30–70%). One patient in the 14-day interval (not previously irradi-
ated) developed congestive heart failure with an LVEF of 30% after
cycle 13 (cumulative epirubicin dose 975 mg m–2). The single
patient with a DILC in the 10-day interval at a dose of 75/135 mg
m–2 (previously irradiated to right chest wall and parasternal region)
developed symptomatic ventricular extrasystoles after cycle 3,
without a decrease in LVEF, and continued treatment for a total of
six cycles. There was no real difference in median changes of
LVEF from baseline and after chemotherapy between patients
previously irradiated to the loco-regional breast/chest (27 patients,
–4%, range –3– +16) and not irradiated patients (8 patients, –7%,
range –24 – +9).
Response rate
Although efficacy was not an aim of this study, formal UICC
criteria were applied to the 29 patients with measurable disease.
After three cycles, i.e. evaluation 20–42 days after the start of
the study treatment an objective response (all partial) was
already observed in 17 of 29 patients (59%, 95% CI, 41–77%),
and there was one patient with progressive disease. Seventeen
patients (stable disease 11 and partial response six) continued
protocol treatment with an interval of ≤ 14 days for a median
number of six cycles (range 4–9) whereby six additional patients
reached a partial response and two partial responders reached a
complete remission. The median interval between the start
of therapy and the first observation of an objective response was
5 weeks (range 3–12 weeks). The best objective response
(complete and partial) for the total study group was 79% (95% CI,
65–94%).
DISCUSSION
The aim of our study was to determine the maximal dose intensity
of epirubicin in combination with paclitaxel in a dose-dense
schedule, supported by G-CSF. With a regimen consisting of
epirubicin 75 mg m–2 and paclitaxel 135 mg m–2 an interval of 10
days was feasible, allowing a median DDI of 52 mg m–2 per week
for epirubicin and 94 mg m–2 per week for paclitaxel, respectively.
Within the 10-day interval it was feasible to increase the paclitaxel
dose to 175 mg m–2 enabling a median DDI of 122 mg m–2 per
week for paclitaxel in combination with 52 mg m–2 per week of
epirubicin. The treatment-schedule related toxicity was relatively
mild, considering the high dose-intensity achieved.
The MTDs of the epirubicin and paclitaxel (3 h) combination in
a 21-day schedule without ‘prophylactic’ haematopoietic growth
factor as first-line treatment in metastatic breast cancer has 
been defined at 50/250 mg m–2, 60/175 mg m–2, 90/175 mg m–2
and 90/200 mg m–2, respectively. Dose-limiting toxicities were
primarily haematological, namely severe neutropenia and febrile
neutropenia (Catimel et al, 1996; Luck et al, 1997; Conte et al,
1997). The DDI in the latter study is 30 mg m–2 per week for
epirubicin and 67 mg m–2 per week for paclitaxel, which is consid-
erable lower than our results of 52 and 122 mg m–2 per week,
respectively.
Interval/dose
14 days 75/135
12 days 75/135
10 days 75/135
10 days 75/175
100
10
1
0,1
A
Neutrophils
1 111315 1 111315 1 111315 1 111315 1 111315 1 111315
cycle 1 cycle 2 cycle 3 cycle 4 cycle 5 cycle 6
Interval/dose
14 days 75/135
12 days 75/135
10 days 75/135
10 days 75/175
600
500
400
300
200
100
0
B
Platelets
1 111315 1 111315 1 111315 1 111315 1 111315 1 111315
cycle 1 cycle 2 cycle 3 cycle 4 cycle 5 cycle 6
Figure 1 Interval shortening of Epirubicin and Paclitaxel plus G-CSF.
Median values per day and range of values at the day of next scheduled
cycle, of consecutive chemotherapy cycles according to protocol: 
(A) neutrophils (´ 109 l–1), (B) platelets (´ 109 l–1)
Table 4 Number of patients (percentage) encountering non-haematological toxicities (WHO-grading) for all cycles with epirubicin and
paclitaxel with G-CSF support
WHO Nausea/ Diarrhoea Stomatitis Neurotoxicity Myalgia Infection Skin
grading vomiting
1 12 (32%) 3 (8%) 8 (22%) 9 (24%) 10 (27%) 0 0
2 12 (32%) 5 (14%) 8 (22%) 3 (8%) 7 (19%) 2 (5%) 3 (8%)
3 1 (3%) 0 3 (8%) 1 (3%) 1 (3%) 2 (5%) 0
400 0 00 0 0In a study of the epirubicin-paclitaxel combination in a 21-day
interval without G-CSF the neutrophil-nadir occurs at day 12 and
the median neutropenia grade 4 duration was 3 days (Conte et al,
1996). In our study, with G-CSF, the neutrophil-nadir was reached
earlier, at day 8, was of very short duration, and was less
pronounced in each consecutive cycle. G-CSF administered on all
days, with the exception of the day of chemotherapy, hastened the
neutrophil recovery after each chemotherapy course, but may also
have had a pre-emptive effect on each consecutive cycle by expan-
sion of the progenitor pool. This so-called pre-emptive G-CSF
effect was, however, not observed earlier (Tjan-Heijnen et al,
1998; de Wit et al, 1996). Thrombocytopenia has not been 
dose-limiting. An important aspect of studies on escalated dose
intensities is whether this can be maintained over repeated cycles.
Conceivably with intervals as short as 10 days and retreatment at
the moment of rapid recovery, the population of progenitor cells
may be vulnerable to the repetitive cytotoxic insults and may
become exhausted after a number of cycles. Although most data
were collected over three cycles, we have not observed signs of
exhaustion, even in the small number of patients treated up to six
cycles. It may well be that treatment with G-CSF up to the day
before the next chemotherapy has protected progenitor cells by
putting them out of the cell cycle, as has been observed with GM-
CSF (Kobrinsky et al, 1999; Vadhan-Raj et al, 1992). Further data
on larger numbers of patients with even more cycles are needed to
determine the absence of cumulative myelosuppression with
certainty.
In the three epirubicin/paclitaxel studies the objective response
rates after a least six cycles were 44%+, 68% (CR in 17%) and 84%
(CR in 18%), respectively (Catimel et al, 1996; Luck et al, 1997;
Conte et al, 1997). These data suggest a dose–response relationship
for epirubicin. In our study, after three short interval cycles a
response rate of 59% had already been observed.
An important argument to investigate epirubicin in combination
with paclitaxel is to circumvent the increased cardiotoxicity of the
doxorubicin/paclitaxel combination. After a median cumulative
doxorubicin dose of 480 mg m–2, 50% of the patients had reductions
of the LVEF below the norm and 20% of the patients developed a
congestive heart failure (Gianni et al, 1995c; Gehl et al, 1996). To
prevent this excess cardiotoxicity the cumulative dose of doxoru-
bicin in this combination needs to be limited to 360 mg m–2, which
makes this regimen not viable in patients pre-treated with doxoru-
bicin containing ajuvant regimens (Hortobagyi et al, 1997). In the
epirubicin/paclitaxel combination studies cardiac toxicity was
observed in 13% (all anthracycline pre-treated), 4% and 6% of the
patients, respectively (Catimel et al, 1996; Luck et al, 1997; Conte et
al, 1997). These data and a recent article suggest less cardiotoxicity
for the epirubicin/paclitaxel combination (Gennari et al, 1999).
Effective dose-dense combination chemotherapy with short
intercyclic intervals affords less opportunity for the emergence and
regrowth of drug-resistant cell clones, a premise upon which this
concept is based (Gilewski and Norton, 1996). Our schedule may
have advantages with respect to both sustained exposure and dose-
dense drug delivery.
In conclusion, with the addition of G-CSF, shortening of inter-
vals of chemotherapy seems to be an effective method of dose
intensification, allowing a dose-intensity of 52 mg m–2 per week of
epirubicin in combination with 122 mg m–2 per week of paclitaxel.
The efficacy and clinical relevance of this approach is now being
investigated in a phase II study.
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